Prateek Paul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Prateek Paul has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ajaswrata Dutta
Radiomitigation Research Department, Institute of Nuclear Medicine and Allied Sciences (INMAS), Defence Research and Development Organization (DRDO), Brig. S.K Mazumdar Marg, Delhi, India
1 shared publication - Dhvani Sandip Vora
Department of Biochemistry and Molecular Biology, Mayo Clinic , Rochester, 13400 E. Shea Blvd. Scottsdale, MN 55905
1 shared publication - Jaspreet Kaur Dhanjal
Department of Computational Biology, Indraprastha Institute of Information Technology Delhi, Okhla Industrial Estate, Phase III, New Delhi, 110020, India
1 shared publication Shashank Yadav
Department of Biomedical Engineering, University of Arizona , 1200 E. University Blvd., Tucson, AZ 85721
1 shared publication- Subodh Kumar
Stem Cell & Tissue Engineering Research Group, Institute of Nuclear Medicine & Allied Sciences (INMAS), Defence Research and Development Organisation (DRDO), Delhi, India
1 shared publication - Suchitra Sharma
Institute of Animal Nutrition and Functional Plant Compounds, University of Veterinary Medicine, Veterinärplatz 1, 1210 Vienna, Austria
1 shared publication
Latest Publications
- Open Access
- 8 January 2026
- Published by The ScienceIn Publishing in Biomedical and Therapeutics Letters
- Vol. 13 (1)
Raloxifene drug enhances stem cell proliferation by inducing the expression of STAT3
Cell proliferation is a complex process that requires the coordination of multiple signaling cascades. In this study, we aimed to identify cell Raloxifene to induce cell proliferation and tissue repair. Raloxifene is an estrogen receptor modulator that helps with osteoporosis post-menopause. We evaluated their role in cell proliferation and molecular mechanism of action via molecular docking, Molecular dynamic (MD) simulation, MM-PBSA analysis, and PCA analysis. Furthermore, the in vitro cell proliferation was evaluated using MTT, BrdU, Ki-67 immunochemistry, cell cycle analysis and in vivo for a whole-body irradiated model for survival by inducing cell proliferation. Our findings suggested that the identified drug, Raloxifene, interacts with STAT3 with -8.1 Kcal/mol binding energy and 0.126±0.177 nm RMSD. In vitro results showed that Raloxifene significantly (pvalue2.5) induced STAT3, followed by Cyclin B, thus enhancing cell proliferation. We also observed a 100 % survival rate in the Raloxifene-treated group compared to the irradiated group. This work may be helpful accelerating proliferation of soft tissue repair in case of combat injuries, radiation injuries, blood pharming, and hematopoietic reconstitution.
- 8 January 2026
- Published by The ScienceIn Publishing in Biomedical and Therapeutics Letters
- Vol. 13 (1)
Open AccessRaloxifene drug enhances stem cell proliferation by inducing the expression of STAT3
Cell proliferation is a complex process that requires the coordination of multiple signaling cascades. In this study, we aimed to identify cell Raloxifene to induce cell proliferation and tissue repair. Raloxifene is an estrogen receptor modulator that helps with osteoporosis post-menopause. We evaluated their role in cell proliferation and molecular mechanism of action via molecular docking, Molecular dynamic (MD) simulation, MM-PBSA analysis, and PCA analysis. Furthermore, the in vitro cell proliferation was evaluated using MTT, BrdU, Ki-67 immunochemistry, cell cycle analysis and in vivo for a whole-body irradiated model for survival by inducing cell proliferation. Our findings suggested that the identified drug, Raloxifene, interacts with STAT3 with -8.1 Kcal/mol binding energy and 0.126±0.177 nm RMSD. In vitro results showed that Raloxifene significantly (pvalue2.5) induced STAT3, followed by Cyclin B, thus enhancing cell proliferation. We also observed a 100 % survival rate in the Raloxifene-treated group compared to the irradiated group. This work may be helpful accelerating proliferation of soft tissue repair in case of combat injuries, radiation injuries, blood pharming, and hematopoietic reconstitution.
- Open Access
- 1 November 2025
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 26 (6)
graphB3—an interpretable graph learning approach for predicting blood–brain barrier permeability
Blood–Brain Barrier (BBB) is a specialized vascular structure that protects the brain by controlling what can pass from the bloodstream into the central nervous system. BBB’s highly selective nature prevents neurotoxins and foreign substances, including drugs, from entering the brain. Understanding and predicting whether a drug can cross the BBB is hence crucial in brain-related diseases. Over the past two decades, deep learning in drug discovery has witnessed an upward trend to reduce the cost, labor, and time for finding potential drugs. Majority of recent deep learning-based studies use molecular-level physiochemical properties of known drugs, which are limited and may not be sufficient to capture patterns. Here, we propose a parameter efficient Graph Convolution-based model, graphB3, which uses detailed information about the atoms in a molecule to predict the BBB permeability of drug candidates, outperforming existing methods. In addition to high predictive performance, graphB3 also offers an explanation of which parts of the molecule are most important for crossing the BBB. graphB3 can be employed to discover new BBB-permeable compounds and potential drugs. A free and easy-to-use graphB3 web server is available at https://dhanjal-lab.iiitd.edu.in/graphb3.html, and a standalone tool available at https://github.com/dhanjal-lab/graphB3.
- 1 November 2025
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 26 (6)
Open AccessgraphB3—an interpretable graph learning approach for predicting blood–brain barrier permeability
Blood–Brain Barrier (BBB) is a specialized vascular structure that protects the brain by controlling what can pass from the bloodstream into the central nervous system. BBB’s highly selective nature prevents neurotoxins and foreign substances, including drugs, from entering the brain. Understanding and predicting whether a drug can cross the BBB is hence crucial in brain-related diseases. Over the past two decades, deep learning in drug discovery has witnessed an upward trend to reduce the cost, labor, and time for finding potential drugs. Majority of recent deep learning-based studies use molecular-level physiochemical properties of known drugs, which are limited and may not be sufficient to capture patterns. Here, we propose a parameter efficient Graph Convolution-based model, graphB3, which uses detailed information about the atoms in a molecule to predict the BBB permeability of drug candidates, outperforming existing methods. In addition to high predictive performance, graphB3 also offers an explanation of which parts of the molecule are most important for crossing the BBB. graphB3 can be employed to discover new BBB-permeable compounds and potential drugs. A free and easy-to-use graphB3 web server is available at https://dhanjal-lab.iiitd.edu.in/graphb3.html, and a standalone tool available at https://github.com/dhanjal-lab/graphB3.